Clostridium difficile infection: New insights into management

Sahil Khanna, Darrell S. Pardi

Research output: Contribution to journalReview articlepeer-review

97 Scopus citations


Clostridium difficile was first described as a cause of diarrhea in 1978 and is now among the leading 3 hospital-acquired infections in the United States, along with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. In the past 2 decades, there has been an increase in the incidence, severity, and recurrence rates of C difficile infection, all of which are associated with poor outcomes. In addition, several novel risk factors and newer treatment methods are emerging, including fidaxomicin therapy, treatment using monoclonal antibodies, and fecal microbiota transplantation, that have shown promise for the treatment of C difficile infection. This review focuses on the changing epidemiology, risk factors, and newer methods for treatment of C difficile infection.

Original languageEnglish (US)
Pages (from-to)1106-1117
Number of pages12
JournalMayo Clinic proceedings
Issue number11
StatePublished - Nov 2012

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Clostridium difficile infection: New insights into management'. Together they form a unique fingerprint.

Cite this